British Medical Journal reported today that reviews of drugs, which are supported by the pharmaceutical industry are less transparent, and are likely to conclude sympathetically as compared to independent reviews, reveals a recently concluded study.
The authors opine that bias in drug trials is a common phenomenon and often favors the trial-sponsor's product. Independent reviews - which can have a more unbiased and systematic approach - are essential to counterbalance this negative approach. This would ensure that doctors and other health professionals have the right and accurate information that they need on drugs.
Adverse Drug Reactions Gender as a Risk Factor
Every effort has been made to cover most of the aspects of Adverse Drug Reactions (A.D.R) in this article. Various types of ADR, few examples of drugs commonly encountered and the possible mechanisms have been included.
Advertisement
The authors, based in Denmark, undertook comparison of 24 pairs of reviews conducted by different people on the same drugs including 7 industry supported reviews. Independent reviews were observed to be of higher quality and less biased than those supported by the pharmaceutical industry.
The industry-supported reviews unilaterally recommended the experimental drug without reservation, while none of the independent corresponding independent reviews reached the same conclusion. Six of them had quality related reservations and two of them noted diminishing effect with increase in number of clinical trial subjects. Seven emphasized on the higher cost of the experimental drug as a problem. In comparison, all industry-supported reviews refrained from mentioning higher cost as a problem, while two actually claimed that the experimental drug was cost-effective.
Industry-supported reviews should be read with caution. Greater transparency, including the inclusion of more information on methodology and the estimated effects of the drugs allow readers to judge the reliability of drug reviews.
Source: IANS
SRM
Industry-supported reviews should be read with caution. Greater transparency, including the inclusion of more information on methodology and the estimated effects of the drugs allow readers to judge the reliability of drug reviews.
Source: IANS
SRM
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial